New study tests Extended-Release paliperidone for schizophrenia in bangladesh
NCT ID NCT07153835
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test the safety and effectiveness of paliperidone extended-release tablets in 505 adults with schizophrenia in Bangladesh. Participants will take the medication once daily for 12 weeks, with doses adjusted as needed. Researchers will measure changes in symptoms using standard rating scales and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paliperidone extended-release (oral tablet)
What this could lead to
If successful, this could confirm that paliperidone is a safe and effective option for managing schizophrenia symptoms in a Bangladeshi population.
What could go wrong
This is an early-phase, single-arm, open-label study with no placebo or comparison group, so results may be less reliable. Side effects like drowsiness, weight gain, or movement problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sher-E-Bangla Medical College Hospital
Barishal, 8200, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••